 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
18th April 2006
F2G
Ltd Announces Key Appointment
Manchester,
England, 18th April 2006 - F2G Limited, specialists in research and
development of new treatments for serious fungal infections in man,
is pleased to announce the appointment of Dr Lloyd Payne as Vice President
of Research and Development.
Dr Payne was previously a senior scientist at Millennium Pharmaceuticals
where he was responsible for the leadership of multidisciplinary drug
discovery project teams based in the UK and the US. Lloyd provided direction
for a number of medicinal chemistry programs from early hit validation
to late stage lead optimisation and has led several successful projects
focused on the development of therapies for inflammatory disorders and
cancer. One such program has since delivered a novel, orally administered
small molecule therapeutic into the clinic.
Lloyd has also held senior scientific and management positions within
Cambridge Discovery Chemistry Ltd and NCE Discovery Ltd where he was
responsible for a number of collaborative medicinal chemistry projects
working with organisations across Europe, Japan and the U.S.
Lloyd’s experience will be invaluable as F2G’s projects move
toward the clinic.
Shane Kelly, Chief Executive of F2G commented “We are delighted
to welcome Lloyd to our world-class team. He has the technical and leadership
skills that will accelerate the development of our programs and bring
new anti fungal drugs through the clinic and onto the market. He is
an outstanding addition to our scientific team.”
F2G’s technologies focus on the development of new and innovative
drug treatments for systemic fungal infections in man. This market is
currently estimated at over five and a half billion dollars annually
and is growing at approximately 20% per year. In addition, there is
new evidence suggesting a correlation between fungal infections and
allergic conditions (including asthma). If proven, this would add significantly
to the growth of the total addressable market.
F2G has developed unique capabilities in the field including proprietary genomic targets, target validation, drug discovery and drug development. They have also amassed unique expertise in the fields of clinical need and corporate and business development specific to the field.
For more
information visit www.f2g.com
Contact:
Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44)
0161 785 1270
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com
Tel +44 (0)161 785 1270 Fax +44 (0)161 785 1273 Email contact@f2g.com